Uncategorized
BioTime Reports First Quarter Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ended March 31, 2018 and recent corporate accomplishments. “With the European CE Mark submission of Renevia, the initiation of patient recruitment for the fourth cohort of our OpRegen clinical trial, sufficient capital to get us well into 2019 and the excellent OpRegen data we reported at ARVO, 2018